Deeptech Digest | News about deeptech

Excalipoint Therapeutics has announced an oversubscribed $68.7m seed financing round to support advancement of its proprietary technology platforms and...

FDA clearance for refractory gout treatment

Jim Cornall - March 26, 2026

Innorna has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application...

Earendil Labs raises $787m to scale AI-driven biologics discovery and development

Jim Cornall - March 26, 2026

Earendil Labs has raised $787m in financing rounds. The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its...

Researchers design drug capable of reversing cognitive decline in Alzheimer’s disease

Jim Cornall - March 25, 2026

A team from the University of Barcelona has designed and validated in animal models a compound with a pioneering...

Shingles vaccine cuts risk of serious cardiac events

Jim Cornall - March 25, 2026

People with heart disease who received a shingles vaccine had nearly half the rate of serious cardiac events a...

Initial data suggest favourable safety profile for Alzheimer’s drug

Jim Cornall - March 25, 2026

Priavoid GmbH has announced promising initial safety data from its ongoing phase 2 trial (PRImus-AD) evaluating its lead candidate,...

Positive results from second-line metastatic breast cancer trial

Jim Cornall - March 24, 2026

Pfizer Inc. has announced positive topline results from the randomised phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with...

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer

Jim Cornall - March 24, 2026

Outrun Therapeutics, a biotech developing protein stabilising therapeutics identified by its proprietary XL discovery platform, has selected its lead...

Fast Track Designation for HAE siRNA therapy

Jim Cornall - March 24, 2026

Argo Biopharmaceutical Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...

‘Molecule Manifesto’ pinpoints key pathways to $1.1tn biotech economy

Jim Cornall - March 23, 2026

Advanced Biotech for Sustainability (AB4S), a cross-sector coalition committed to unlocking the full environmental potential of advanced biotechnology, published...

New mechanism driving breast cancer progression

Jim Cornall - March 23, 2026

A research group led by Cecilia Sahlgren at Åbo Akademi University in Finland and the InFLAMES Research Flagship has...

Mutation strength in a single gene shapes tumour behaviour

Jim Cornall - March 23, 2026

Cancer is often thought of as a single disease. Yet even tumours that arise in the same organ can...

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease

Jim Cornall - March 20, 2026

On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director...

EDPB and EDPS support harmonisation of clinical trials under European Biotech Act

Jim Cornall - March 19, 2026

The European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) have adopted a Joint Opinion on...

IND clearance for focal epilepsy cell therapy

Jim Cornall - March 19, 2026

Unixell Biotech’s UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the...

New data on achondroplasia presented

Jim Cornall - March 19, 2026

BioMarin Pharmaceutical Inc. has announced positive new data from studies of VOXZOGO (vosoritide) in children with achondroplasia in ongoing...

GenScript opens European mRNA hub

Jim Cornall - March 18, 2026

GenScript has officially opened its first European mRNA production site in Delft, the Netherlands. The Delft facility strengthens GenScript's transatlantic...

Fast Track Designation for myotonic dystrophy type 1 drug

Jim Cornall - March 18, 2026

ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ATX-01...

Fast Track Designation for Netherton syndrome treatment

Jim Cornall - March 18, 2026

Quoin Pharmaceuticals Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to...

New preclinical data for POLG disease treatment

Jim Cornall - March 17, 2026

Pretzel Therapeutics has presented new preclinical data on the lead therapeutic in its bioenergetics restoration franchise, PX578, at the...

Enodia Therapeutics acquires preclinical assets from Kezar Life Sciences

Jim Cornall - March 17, 2026

Enodia Therapeutics has acquired Kezar Life Sciences’ assets from its Sec61-based discovery and development programme. The acquisition enables Enodia to...